207 related articles for article (PubMed ID: 36136102)
1. Combined [68 Ga]Ga-PSMA-11 and low-dose 2-[18F]FDG PET/CT using a long-axial field of view scanner for patients referred for [177Lu]-PSMA-radioligand therapy.
Alberts I; Schepers R; Zeimpekis K; Sari H; Rominger A; Afshar-Oromieh A
Eur J Nucl Med Mol Imaging; 2023 Feb; 50(3):951-956. PubMed ID: 36136102
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. The Triple-Tracer strategy against Metastatic PrOstate cancer (3TMPO) study protocol.
Pouliot F; Beauregard JM; Saad F; Trudel D; Richard PO; Turcotte É; Rousseau É; Probst S; Kassouf W; Anidjar M; Camirand Lemyre F; Bouvet GF; Neveu B; Tétu A; Guérin B
BJU Int; 2022 Sep; 130(3):314-322. PubMed ID: 34674367
[TBL] [Abstract][Full Text] [Related]
4. Authors' reply to Dr. Paolo Duarte: Combined [68Ga]Ga-PSMA-11 and low-dose [18F]FDG PET/CT using a long-axial field of view scanner for patients referred for [177Lu]-PSMA-radioligand therapy.
Alberts I; Schepers R; Zeimpekis K; Sari H; Rominger A; Afshar-Oromieh A
Eur J Nucl Med Mol Imaging; 2023 Feb; 50(3):644-647. PubMed ID: 36543899
[No Abstract] [Full Text] [Related]
5. Dual FDG/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT.
Rosar F; Burgard C; David S; Marlowe RJ; Bartholomä M; Maus S; Petto S; Khreish F; Schaefer-Schuler A; Ezziddin S
Sci Rep; 2024 May; 14(1):11271. PubMed ID: 38760451
[TBL] [Abstract][Full Text] [Related]
6. Clinical performance of long axial field of view PET/CT: a head-to-head intra-individual comparison of the Biograph Vision Quadra with the Biograph Vision PET/CT.
Alberts I; Hünermund JN; Prenosil G; Mingels C; Bohn KP; Viscione M; Sari H; Vollnberg B; Shi K; Afshar-Oromieh A; Rominger A
Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2395-2404. PubMed ID: 33797596
[TBL] [Abstract][Full Text] [Related]
7. Differentiating benign and malignant pancreatic masses: Ga-68 PSMA PET/CT as a new diagnostic avenue.
Krishnaraju VS; Kumar R; Mittal BR; Sharma V; Singh H; Nada R; Bal A; Rohilla M; Singh H; Rana SS
Eur Radiol; 2021 Apr; 31(4):2199-2208. PubMed ID: 33001304
[TBL] [Abstract][Full Text] [Related]
8. Letter to the editor: Combined [
Duarte PS
Eur J Nucl Med Mol Imaging; 2023 Feb; 50(3):642-643. PubMed ID: 36258051
[No Abstract] [Full Text] [Related]
9. Feasibility of late acquisition [68Ga]Ga-PSMA-11 PET/CT using a long axial field-of-view PET/CT scanner for the diagnosis of recurrent prostate cancer-first clinical experiences.
Alberts I; Prenosil G; Mingels C; Bohn KP; Viscione M; Sari H; Rominger A; Afshar-Oromieh A
Eur J Nucl Med Mol Imaging; 2021 Dec; 48(13):4456-4462. PubMed ID: 34155538
[TBL] [Abstract][Full Text] [Related]
10. Clinical Translation and First In-Human Use of [
Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F
Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic efficacy, prognostic variables and clinical outcome of
Suman S; Parghane RV; Joshi A; Prabhash K; Bakshi G; Talole S; Banerjee S; Basu S
Br J Radiol; 2019 Dec; 92(1104):20190380. PubMed ID: 31600089
[TBL] [Abstract][Full Text] [Related]
12. Neuron-specific enolase has potential value as a biomarker for [
Rosar F; Ribbat K; Ries M; Linxweiler J; Bartholomä M; Maus S; Schreckenberger M; Ezziddin S; Khreish F
EJNMMI Res; 2020 May; 10(1):52. PubMed ID: 32449086
[TBL] [Abstract][Full Text] [Related]
13. The roles of 68 Ga-PSMA PET/CT and 18 F-FDG PET/CT imaging in patients with triple-negative breast cancer and the association of tissue PSMA and claudin 1, 4, and 7 levels with PET findings.
Arslan E; Ergül N; Beyhan E; Erol Fenercioglu Ö; Sahin R; Cin M; Battal Havare S; Can Trabulus FD; Mermut Ö; Akbas S; Fikret Çermik T
Nucl Med Commun; 2023 Apr; 44(4):284-290. PubMed ID: 36756767
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic value of
Chen R; Wang Y; Shi Y; Zhu Y; Xu L; Huang G; Liu J
Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2970-2977. PubMed ID: 33528607
[TBL] [Abstract][Full Text] [Related]
15. Prognostic implications of dual tracer PET/CT: PSMA ligand and [
Michalski K; Ruf J; Goetz C; Seitz AK; Buck AK; Lapa C; Hartrampf PE
Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):2024-2030. PubMed ID: 33336265
[TBL] [Abstract][Full Text] [Related]
16. Head-to-head comparison of [
Souza SPM; Frasson FC; Takahashi MES; Duarte GBO; Castro VP; Pericole FV; Velloso LA; De Souza CA; Lorand-Metze I; Santos AO; Ramos CD
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2432-2440. PubMed ID: 36988710
[TBL] [Abstract][Full Text] [Related]
17.
Parghane RV; Basu S
J Nucl Med Technol; 2023 Sep; 51(3):261-262. PubMed ID: 36041875
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic Value of 68Ga PSMA-11 PET/CT Imaging of Brain Tumors-Preliminary Analysis.
Sasikumar A; Joy A; Pillai MR; Nanabala R; Anees K M; Jayaprakash PG; Madhavan J; Nair S
Clin Nucl Med; 2017 Jan; 42(1):e41-e48. PubMed ID: 27846000
[TBL] [Abstract][Full Text] [Related]
19.
Parihar AS; Mittal BR; Kumar R; Shukla J; Bhattacharya A
Thyroid; 2020 Apr; 30(4):557-567. PubMed ID: 31870227
[No Abstract] [Full Text] [Related]
20. Impact of the new ultra-high sensitivity mode in a long axial field-of-view PET/CT.
Mingels C; Weidner S; Sari H; Buesser D; Zeimpekis K; Shi K; Alberts I; Rominger A
Ann Nucl Med; 2023 May; 37(5):310-315. PubMed ID: 36913094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
